Related Experiment Video
Updated: Jul 1, 2026

Purification of Ubiquitinated p53 Proteins from Mammalian Cells
Published on: March 21, 2022
Ubiquitin-specific Peptidase 53 Suppresses Head/Neck Tumorigenesis by Stabilizing FBXW7
Min-Hong Wang1, Mei-Ren Pan2, Yu-Hsuan Hung3
1Division of Hematology and Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan, R.O.C.
Background/Aim:
Head and neck squamous cell carcinoma (HNSC) remains a cancer with a poor prognosis despite treatment options of surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy. Novel targets and therapeutics await identification. The aim of this study was to identify such targets and therapeutics using a prognosis-based approach and validate them experimentally.
Materials And Methods:
UALCAN, cBioPortal, Reactome, L2S2, and TIMER3 were used to study the prognosis, gene expression, pathways, therapeutics, and immunity of HNSC, respectively. Ubiquitin-specific peptidase 53 (USP53) was among the top prognostic factors in HNSC based on the UALCAN analysis. The FaDu human HNSC cell line, which exhibits high USP53 expression, was used in the subsequent experiments. Cell proliferation, cell cycle, sphere formation, and proximity ligation assays were performed.
Results:
USP53 was found to be downregulated in HNSC and predicted a better prognosis. The pathway and therapeutic analyses revealed that USP53-low HNSC was enriched in cell-cycle dysregulation and could be mimicked by a cyclin-dependent kinase inhibitor (CDKi). In vitro, USP53 knockdown increased HNSC proliferation and sensitivity to CDKi in two- and three-dimensional assays. Multiomic analyses revealed that USP53 may deubiquitinate F-box and WD repeat domain-containing 7 (FBXW7) and subsequently suppress HNSC proliferation. This was verified using a proximity ligation assay (PLA). Lastly, USP53 is negatively associated with M2 macrophages.
Conclusion:
USP53 functions as a critical tumor suppressor in HNSC by post-translationally stabilizing the E3 ubiquitin ligase FBXW7. This molecular mechanism establishes a targetable cell-cycle vulnerability sensitive to cyclin-dependent kinase inhibitors and uncovers a direct connection between deubiquitinase activity and tumor immune cell infiltration.
Insights
Ubiquitin-specific peptidase 53 (USP53) acts as a tumor suppressor in head and neck squamous cell carcinoma (HNSC). Lower USP53 levels increase proliferation and sensitivity to cyclin-dependent kinase inhibitors, revealing a new therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Head and neck squamous cell carcinoma (HNSC) has a poor prognosis despite current treatments.
- Identifying novel therapeutic targets is crucial for improving HNSC patient outcomes.
Purpose of the Study:
- To identify and experimentally validate novel prognostic factors and therapeutic targets in HNSC.
- To investigate the role of Ubiquitin-specific peptidase 53 (USP53) in HNSC progression and treatment response.
Main Methods:
- Bioinformatic analyses using UALCAN, cBioPortal, Reactome, L2S2, and TIMER3.
- Experimental validation in the FaDu HNSC cell line, including proliferation, cell cycle, and sphere formation assays.
- Proximity ligation assays to confirm protein interactions and multiomic analyses.
Main Results:
- USP53 was identified as a downregulated gene in HNSC, correlating with a better prognosis.
- USP53 knockdown enhanced HNSC proliferation and sensitivity to cyclin-dependent kinase inhibitors (CDKi).
- USP53 was found to stabilize FBXW7, suppressing HNSC proliferation and negatively associating with M2 macrophages.
Conclusions:
- USP53 functions as a tumor suppressor in HNSC by stabilizing FBXW7, impacting cell-cycle regulation.
- This mechanism highlights a targetable vulnerability to CDKi and links deubiquitinase activity to tumor immunity.
Related Concept Videos
Abnormal Proliferation
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein.
Anaphase Promoting Complex
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
Hedgehog Signaling Pathway
Negative Regulator Molecules

